| Citation: |
LI Ping, GUO Xu. Current Status of Off-label Use of Denosumab in Bone Tumor and Bone Diseases[J]. Cancer Research on Prevention and Treatment, 2023, 50(3): 316-320. DOI: 10.3971/j.issn.1000-8578.2023.22.0860
|
Denosumab is a monoclonal antibody against the receptor activator of nuclear factor-κB (RANK) ligand (RANKL) that significantly inhibits osteoclast activity and has been approved to treat osteoporosis, giant cell tumor of bone, and prophylactic as well as therapeutic entities for bone metastasis. However, the imbalance of RANKL/RANK/OPG has also been implicated in the pathogenesis of several other rare bone diseases and tumor-like disorders, including aneurysmal bone cyst, fibrous dysplasia of bone, and Langerhans cell histiocytosis. Nevertheless, there have been various clinical reports although these diseases have not been approved for indications. The review aims to summarize the available evidence for the off-label use of denosumab in metabolic bone diseases and tumor-like disorders and provide a reference for clinical diagnosis and treatment.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Anastasilakis AD, Toulis KA, Polyzos SA, et al. RANKL inhibition for the management of patients with benign metabolic bone disorders[J]. Expert Opin Investig Drugs, 2009, 18(8): 1085-1102. doi: 10.1517/13543780903048929
|
| [2] |
Anastasilakis AD, Toulis KA, Polyzos SA, et al. Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab[J]. Ther Clin Risk Manag, 2012, 8: 295-306.
|
| [3] |
Kurucu N, Akyuz C, Ergen FB, et al. Denosumab treatment in aneurysmal bone cyst: Evaluation of nine cases[J]. Pediatr Blood Cancer, 2018, 65(4): e26926.
|
| [4] |
Palmerini E, Ruggieri P, Angelini A, et al. Denosumab in patients with aneurysmal bone cysts: A case series with preliminary results[J]. Tumori, 2018, 104(5): 344-351.
|
| [5] |
Pelle DW, Ringler JW, Peacock JD, et al. Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response[J]. Transl Res, 2014, 164(2): 139-148.
|
| [6] |
Yamagishi T, Kawashima H, Ogose A, et al. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors[J]. PLoS One, 2016, 11(5): e0154680.
|
| [7] |
Raux S, Bouhamama A, Gaspar N, et al. Denosumab for treating aneurysmal bone cysts in children[J]. Orthop Traumatol Surg Res, 2019, 105(6): 1181-1185.
|
| [8] |
Lange T, Stehling C, Fröhlich B, et al. Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts[J]. Eur Spine J, 2013, 22(6): 1417-1422. doi: 10.1007/s00586-013-2715-7
|
| [9] |
Pauli C, Fuchs B, Pfirrmann C, et al. Response of an aggressive periosteal aneurysmal bone cyst (ABC) of the radius to denosumab therapy[J]. World J Surg Oncol, 2014, 12: 17. doi: 10.1186/1477-7819-12-17
|
| [10] |
Dubory A, Missenard G, Domont J, et al. Interest of Denosumab for the Treatment of Giant-cells Tumors and Aneurysmal Bone Cysts of the Spine. About Nine Cases[J]. Spine (Phila Pa 1976), 2016, 41(11): E654-E660. doi: 10.1097/BRS.0000000000001350
|
| [11] |
Ghermandi R, Terzi S, Gasbarrini A, et al. Denosumab: non-surgical treatment option for selective arterial embolization resistant aneurysmal bone cyst of the spine and sacrum. Case report[J]. Eur Rev Med Pharmacol Sci, 2016, 20(17): 3692-3695.
|
| [12] |
Ntalos D, Priemel M, Schlickewei C, et al. Therapeutic Management of a Substantial Pelvic Aneurysmatic Bone Cyst Including the Off-Label Use of Denosumab in a 35-Year-Old Female Patient[J]. Case Rep Orthop, 2017, 2017: 9125493.
|
| [13] |
Patel RS, Dhamne CA, Gopinathan A, et al. Denosumab: a potential treatment option for aneurysmal bone cyst of the atlas[J]. Eur Spine J, 2018, 27(Suppl 3): 494-500.
|
| [14] |
Kulkarni AG, Patel A. Denosumab: A potential new treatment option for recurrent Aneurysmal Bone Cyst of the spine[J]. SICOT J, 2019, 5: 10. doi: 10.1051/sicotj/2019007
|
| [15] |
Dürr HR, Grahneis F, Baur-Melnyk A, et al. Aneurysmal bone cyst: results of an off label treatment with Denosumab[J]. BMC Musculoskelet Disord, 2019, 20(1): 456.
|
| [16] |
de Castro LF, Burke AB, Wang HD, et al. Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease Burden[J]. J Bone Miner Res, 2019, 34(2): 290-294. doi: 10.1002/jbmr.3602
|
| [17] |
Boyce AM, Chong WH, Yao J, et al. Denosumab treatment for fibrous dysplasia[J]. J Bone Miner Res, 2012, 27(7): 1462-1470. doi: 10.1002/jbmr.1603
|
| [18] |
Ganda K, Seibel MJ. Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases[J]. Osteoporosis Int, 2014, 25(2): 777-782. doi: 10.1007/s00198-013-2585-1
|
| [19] |
Benhamou J, Gensburger D, Chapurlat R. Transient improvement of severe pain from fibrous dysplasia of bone with denosumab treatment[J]. Joint Bone Spine, 2014, 81(6): 549-550.
|
| [20] |
Eller-Vainicher C, Rossi DS, Guglielmi G, et al. Prompt clinical and biochemical response to denosumab in a young adult patient with craniofacial fibrous dysplasia[J]. Clin Cases Mineral Bone Metab, 2016, 13(3): 253-256.
|
| [21] |
Meier ME, van der Bruggen W, van de Sande MAJ, et al. Regression of fibrous dysplasia in response to denosumab therapy: a report of two cases[J]. Bone Rep, 2021, 14: 101058. doi: 10.1016/j.bonr.2021.101058
|
| [22] |
Majoor BCJ, Papapoulos SE, Dijkstra PDS, et al. Denosumab in Patients With Fibrous Dysplasia Previously Treated With Bisphosphonates[J]. J Clin Endocrinol Metab, 2019, 104(12): 6069-6078. doi: 10.1210/jc.2018-02543
|
| [23] |
Polyzos SA, Anastasilakis AD, Litsas I, et al. Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease[J]. J Bone Miner Metab, 2010, 28(6): 706-712. doi: 10.1007/s00774-010-0198-8
|
| [24] |
Girschikofsky M, Arico M, Castillo D, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net[J]. Orphanet J Rare Dis, 2013, 8: 72. doi: 10.1186/1750-1172-8-72
|
| [25] |
Badalian-Very G, Vergilio JA, Fleming M, et al. Pathogenesis of Langerhans Cell Histiocytosis[J]. Annu Rev Pathol, 2013, 8: 1-20. doi: 10.1146/annurev-pathol-020712-163959
|
| [26] |
Salotti JA, Nanduri V, Pearce MS, et al. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland[J]. Arch Dis Child, 2009, 94(5): 376-380. doi: 10.1136/adc.2008.144527
|
| [27] |
Makras P, Polyzos SA, Anastasilakis AD, et al. Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans Cell Histiocytosis[J]. J Clin Endocrinol Metab, 2012, 97(4): E618-E621. doi: 10.1210/jc.2011-2962
|
| [28] |
Makras P, Salagianni M, Revelos K, et al. Rationale for the Application of RANKL Inhibition in the Treatment of Langerhans Cell Histiocytosis[J]. J Clin Endocrinol Metab, 2015, 100(2): E282-E286. doi: 10.1210/jc.2014-2654
|
| [29] |
Bredell M, Rordorf T, Kroiss S, et al. Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study[J]. J Oral Maxillofac Surg, 2018, 76(4): 775-784. doi: 10.1016/j.joms.2017.09.013
|
| [30] |
Shojaei S, Jamshidi S, Roshanaei G, et al. Immunohistochemical Expression of Mast Cell in Oral Reactive Lesions[J]. J Dent (Shiraz), 2015, 16(1 Suppl): 10-14.
|
| [31] |
Naidu A, Malmquist MP, Denham CA, et al. Management of Central Giant Cell Granuloma With Subcutaneous Denosumab Therapy[J]. J Oral Maxillofac Surg, 2014, 72(12): 2469-2484. doi: 10.1016/j.joms.2014.06.456
|
| [32] |
Schreuder WH, Coumou AW, Kessler PAHW, et al. Alternative Pharmacologic Therapy for Aggressive Central Giant Cell Granuloma: Denosumab[J]. J Oral Maxillofac Surg, 2014, 72(7): 1301-1309. doi: 10.1016/j.joms.2014.02.017
|
| [33] |
Polyzos SA, Anastasilakis AD, Terpos E. Paget's disease of bone: emphasis on treatment with zoledronic acid[J]. Expert Rev Endocrinol Metab, 2009, 4(5): 423-434. doi: 10.1586/eem.09.35
|
| [34] |
Schwarz P, Rasmussen AQ, Kvist TM, et al. Paget's disease of the bone after treatment with Denosumab: A case report[J]. Bone, 2012, 50(5): 1023-1025. doi: 10.1016/j.bone.2012.01.020
|
| [35] |
Kostine M, Mehsen-Cetre N, Bannwarth B. Denosumab-induced severe hypocalcemia in a patient with Paget's disease of bone and impaired renal function[J]. Therapie, 2017, 72(3): 383-385. doi: 10.1016/j.therap.2016.07.003
|
| [36] |
Kuthiah N, Er C. Effective Treatment of Paget's Disease of the Bone in a Chinese Woman[J]. Ann Acad Med Singap, 2018, 47(12): 528-530. doi: 10.47102/annals-acadmedsg.V47N12p528
|
| [37] |
Verma V, Puri A, Shah S, et al. Giant Cell Tumor Developing in Paget's Disease of Bone: A Case Report with Review of Literature[J]. J Orthop Case Rep, 2016, 6(4): 103-107.
|
| [38] |
Tanaka T, Slavin J, McLachlan SA, et al. Anti-osteoclastic agent, denosumab, for a giant cell tumor of the bone with concurrent Paget's disease: A case report[J]. Oncol Lett, 2017, 13(4): 2105-2108. doi: 10.3892/ol.2017.5693
|
| [39] |
Grasemann C, Schündeln MM, Hövel M, et al. Effects of RANK-Ligand Antibody (Denosumab) Treatment on Bone Turnover Markers in a Girl With Juvenile Paget's Disease[J]. J Clin Endocrinol Metab, 2013, 98(8): 3121-3126. doi: 10.1210/jc.2013-1143
|
| [40] |
Polyzos SA, Singhellakis PN, Naot D, et al. Denosumab Treatment for Juvenile Paget's Disease: Results From Two Adult Patients With Osteoprotegerin Deficiency ("Balkan" Mutation in the TNFRSF11B Gene)[J]. J Clin Endocrinol Metab, 2014, 99(3): 703-707. doi: 10.1210/jc.2013-3762
|
| [41] |
Polyzos SA, Cundy T, Mantzoros CS. Juvenile Paget disease[J]. Metabolism, 2018, 80: 15-26. doi: 10.1016/j.metabol.2017.10.007
|
| [42] |
Matsumoto T, Naito M, Hirose J, et al. Gorham-Stout Syndrome of the Shoulder Girdle Successfully Controlled by Antiresorptive Agents: A Report of 2 Cases[J]. JBJS Case Connect, 2019, 9(2): e0285. doi: 10.2106/JBJS.CC.18.00285
|
| [43] |
Nozawa A, Ozeki M, Hori T, et al. Fatal Progression of Gorham-Stout Disease with Skull Base Osteomyelitis and Lateral Medullary Syndrome[J]. Intern Med, 2019, 58(13): 1929-1933. doi: 10.2169/internalmedicine.2118-18
|
| 1. |
石秀峰，袁伶俐，陈淑芳，张先棠，施华，欧如梦，张莉. 地舒单抗联合椎体成形术治疗胸腰椎压缩性骨折的疗效. 国际骨科学杂志. 2024(02): 146-149 .
| |
| 2. |
宓凌彬，赵震宇，江礼俊，刘铁龙. 地舒单抗治疗骨质疏松性骨折的系统性评价. 中国药物应用与监测. 2024(04): 489-493 .
| |
| 3. |
蓝清华，曾庆芳，肖威，钟建明，詹涛，邱流进. 地舒单抗治疗晚期鼻咽癌骨转移的效果及安全性. 中国当代医药. 2024(28): 52-55+60 .
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: